neuro-oncology
(3)
Jason Levin Stayed With the Bet Long Enough for the Science to Change
For more than a decade, the Orbus co-founder helped carry one drug through financing, patents and a 343-patient trial. Then a new tumor classification changed the question - and the company’s next chapter.
Per Langoe
Per Langoe is the CEO of GT Medical Technologies, the Tempe, Arizona company behind GammaTile, an FDA-cleared radiation therapy tile that gets sewn into the brain the same moment a tumor is removed. He arrived in February 2024 after co-founding and selling Palette Life Sciences to Teleflex for $600 million, bringing more than two decades in radiation oncology commercialization from Pharmacia, Q-Med, Galderma and Nestle Skin Health.
Ben Woodington
Ben Woodington is the co-founder and CEO of Coherence Neuro, a deep-tech company building SOMA-1, a button-sized, MRI-safe brain-computer interface that listens to and electrically modulates brain tumors from the inside. A Cambridge-trained chemist-turned-engineer who once built smart inhalers and minimally invasive spinal-cord interfaces, Woodington pivoted his neurotechnology to oncology after realizing almost no one was applying neural-interface engineering to cancer. He argues electricity should become the fourth pillar of cancer therapy alongside surgery, drugs, and radiation, and raised a $10M seed in late 2025 to take the work toward first human trials.